StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / calliotx.com

Callio Therapeutics

Callio Therapeutics (calliotx.com): 2 changes recorded in its website history since March 2025. Homepage last checked 6 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. HiringBetween and

    Added a careers page.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagecurrent websiteHistorical capture not publicly availableLink to observation
  2. HeadlineBetween and
    BeforeRealizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes
    AfterBlocking Cancer’s Escape.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 4 March 2025

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes

We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.

Homepage

Compliance claims on the website
FDA APPROVED · FDA-APPROVED
Funding statements on the website
AskBio and was part of the team that raised a USD 120Mn series B extension.

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. October 2026 – November 2026 · 3 captures · latest observed messagingBlocking Cancer’s Escape.

    Callio Therapeutics is advancing dual-payload antibody-drug conjugates (ADCs) designed to block cancer’s escape routes and deliver durable responses for underserved patient populations.

    This wording observed 6 November 2026.

    current websiteHistorical capture not publicly available
    Inspect 3 captures in this group
    • 3 October 2026 · Blocking Cancer’s Escape. archived page
    • 27 October 2026 · Blocking Cancer’s Escape. archived page
    • 6 November 2026 · Blocking Cancer’s Escape. current websiteHistorical capture not publicly available
  2. March 2025 – March 2026 · 3 capturesRealizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes

    We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.

    This wording observed 25 March 2026.

    archived page
    Inspect 3 captures in this group
    • 4 March 2025 · Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes archived page
    • 30 November 2025 · Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes archived page
    • 25 March 2026 · Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes archived page

Cite this record

StartupHistory, “Callio Therapeutics” company record, https://startuphistory.org/c/calliotx.com

Machine-readable: /c/calliotx.com.json. How changes are found: method.